Cwm LLC Sells 398 Shares of Catalent, Inc. (NYSE:CTLT)

Cwm LLC cut its position in Catalent, Inc. (NYSE:CTLT) by 9.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,670 shares of the company’s stock after selling 398 shares during the quarter. Cwm LLC’s holdings in Catalent were worth $222,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Thurston Springer Miller Herd & Titak Inc. bought a new stake in shares of Catalent in the second quarter worth $42,000. Longfellow Investment Management Co. LLC lifted its holdings in Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock worth $55,000 after buying an additional 305 shares during the period. GAMMA Investing LLC grew its position in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after buying an additional 212 shares during the last quarter. Sound Income Strategies LLC increased its stake in shares of Catalent by 4,466.7% in the first quarter. Sound Income Strategies LLC now owns 1,370 shares of the company’s stock valued at $77,000 after buying an additional 1,340 shares during the period. Finally, Federated Hermes Inc. increased its stake in shares of Catalent by 456.6% in the second quarter. Federated Hermes Inc. now owns 2,833 shares of the company’s stock valued at $159,000 after buying an additional 2,324 shares during the period.

Catalent Stock Performance

Shares of CTLT stock opened at $59.92 on Wednesday. Catalent, Inc. has a one year low of $31.80 and a one year high of $61.20. The company has a market cap of $10.84 billion, a P/E ratio of -9.82, a P/E/G ratio of 2.14 and a beta of 1.15. The firm has a 50-day moving average of $60.14 and a 200-day moving average of $57.84. The company has a debt-to-equity ratio of 1.35, a current ratio of 2.52 and a quick ratio of 1.96.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. Equities research analysts forecast that Catalent, Inc. will post 0.95 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, insider David Mcerlane sold 1,994 shares of the firm’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Scott Gunther sold 666 shares of the business’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the sale, the senior vice president now owns 39,635 shares in the company, valued at approximately $2,360,264.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 12,730 shares of company stock valued at $751,870. 0.31% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

CTLT has been the subject of several recent analyst reports. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. Royal Bank of Canada reiterated a “sector perform” rating and set a $63.50 price target on shares of Catalent in a report on Thursday, July 11th. StockNews.com began coverage on Catalent in a research note on Saturday, October 12th. They issued a “hold” rating on the stock. William Blair restated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Nine analysts have rated the stock with a hold rating, According to data from MarketBeat, Catalent has a consensus rating of “Hold” and a consensus target price of $59.83.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.